Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Lyrica CR Extended-Release Tablets CV

Pfizer news release; 2017 Oct 12

Pfizer Inc. has announced that the US Food and Drug Administration (FDA) has approved Lyrica CR (pregabalin) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN).

Dosage/administration: Lyrica CR should be administered once daily after an evening meal. It should be swallowed whole and should not be split, crushed, or chewed. The initial dose for DPN is 165 mg/day; the maximum dose is 330 mg/day within 1 week. For PHN, the initial dose is 165 mg/day; the maximum dose is 330 mg/day within 1 week, with a maximum dose of 660 mg/day.

Adverse reactions: The most common adverse reactions reported with Lyrica CR were dizziness, somnolence, headache, fatigue, peripheral edema, nausea, blurred vision, dry mouth, and weight gain.


US FDA approves LYRICA CR (pregabalin) extended-release tablets CV. [news release]. New York, NY: Pfizer Inc. October 12, 2017. Accessed October 30, 2017.

This Week's Must Reads

Neurofilament Light Protein and Movement Disorders, JAMA Neurology; ePub 2018 Dec 3; Olsson, et al

Levodopa-Induced Dyskinesia in PD Assessed, Neurology; ePub 2018 Nov 7; Turcano, et al

Regional Brain Volumes Predict DBS Motor Response , Parkinsonism Relat Disord; ePub 2018 Nov 28; Younce, et al

Medical Decision-Making Examined in PSP, Parkinsonism Relat Disord; ePub 2018 Nov 26; Gerstenecker, et al

Cortical Dynamics Examined in Essential Tremor, Mov Disord; ePub 2018 Oct 21; Roy, Coombes, et al

Must Reads in FDA Actions

FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14

FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6

FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23